Portal de Periódicos da CAPES

An update of safety of clinically used atypical antipsychotics

2016; Taylor & Francis; Volume: 15; Issue: 10 Linguagem: Inglês

10.1080/14740338.2016.1201475

1744-764X

Laura Orsolini, Carmine Tomasetti, A. Valchera, R. Vecchiotti, Ilaria Matarazzo, Federica Vellante, F. Iasevoli, Elisabetta Filomena Buonaguro, Michele Fornaro, Annastasia Fiengo, Giovanni Martinotti, Monica Mazza, Giampaolo Perna, Alessandro Carano, Andrea de Bartolomeis, Massimo Di Giannantonio, Domenico De Berardis,

Bipolar Disorder and Treatment

Introduction: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/‘typical’ APs.Areas covered: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone)).Expert opinion: A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.